Clinical Trial Update: Adjuvant Treatment of ALK-positive Non-small Cell Lung Cancer with Ensartinib Guided by MRD [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating adjuvant treatment of ALK-positive non-small cell lung cancer with ensartinib guided by MRD (minimal residual disease).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Ensartinib (Ensartinib)

Snippet

Sponsor: Peking University Cancer Hospital & Institute | Conditions: NSCLC, Stage I, II, IIIA, IIIB | Phase 2 | Status: NOT_YET_RECRUITING